---
document_datetime: 2025-12-02 07:00:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/skytrofa.html
document_name: skytrofa.html
version: success
processing_time: 0.1113002
conversion_datetime: 2025-12-24 20:25:24.378998
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Skytrofa (previously Lonapegsomatropin Ascendis Pharma)

[RSS](/en/individual-human-medicine.xml/67514)

##### Authorised

This medicine is authorised for use in the European Union

lonapegsomatropin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Skytrofa (previously Lonapegsomatropin Ascendis Pharma)](#news-on)
- [More information on Skytrofa (previously Lonapegsomatropin Ascendis Pharma)](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lonapegsomatropin Ascendis Pharma is a medicine that is used to improve growth in children and adolescents who do not produce enough growth hormone (growth hormone deficiency or GHD). The medicine is intended for children and adolescents from 3 up to 18 years of age.

GHD is rare, and Lonapegsomatropin Ascendis Pharma was designated an 'orphan medicine' (a medicine used in rare diseases) on 17 October 2019. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3192213](/en/medicines/human/orphan-designations/eu-3-19-2213) .

Lonapegsomatropin Ascendis Pharma contains the active substance lonapegsomatropin.

Expand section

Collapse section

## How is Lonapegsomatropin Ascendis Pharma used?

Lonapegsomatropin Ascendis Pharma can only be obtained with a prescription and treatment should be started and monitored by a doctor who is qualified and experienced in the diagnosis and treatment of GHD in children.

The medicine is available as an injection of various strengths, to be given under the skin once a week. The starting dose depends on body weight and is then adjusted individually by the doctor based on response. Patients or their caregivers can inject the dose themselves after appropriate training.

For more information about using Lonapegsomatropin Ascendis Pharma, see the package leaflet or contact your doctor or pharmacist.

## How does Lonapegsomatropin Ascendis Pharma work?

Growth hormone is released by the pituitary gland (a gland at the base of the brain). It is important for growth during childhood and adolescence, and it also affects how the body handles proteins, fat and carbohydrates. The active substance in the medicine, lonapegsomatropin,is a version of human growth hormone (somatropin) that has been attached to a 'carrier' that protects it from being removed from the body too quickly. The medicine slowly releases growth hormone into the body after injection, meaning that injections do not have to be given every day.

## What benefits of Lonapegsomatropin Ascendis Pharma have been shown in studies?

Lonapegsomatropin Ascendis Pharma given once weekly in equivalent doses has been shown to be as effective as daily somatropin injections in a main study involving 161 patients aged 3 to 12 years with previously untreated GHD. The study measured the average rate of growth (height velocity) over a year, which was 11.2 cm per year in the group given lonapegsomatropin and 10.3 cm per year in those given daily somatropin (average growth rate in both groups before treatment was 3.9 cm per year). The company also presented the results of supportive studies including patients who had previously had growth hormone treatment.

## What are the risks associated with Lonapegsomatropin Ascendis Pharma?

The most common side effects with Lonapegsomatropin Ascendis Pharma (which may affect up to around 1 in 10 people) are headache, joint pain, secondary hypothyroidism (a type of low thyroid function) and reactions at the injection site such as redness, pain, itching or swelling.

For the full list of side effects of Lonapegsomatropin Ascendis Pharma, see the package leaflet.

Growth hormone medicines like Lonapegsomatropin Ascendis Pharma must not be used if the patient has an active tumour or an acute life-threatening illness. The medicine must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). For the full list of restrictions, see the package leaflet.

## Why is Lonapegsomatropin Ascendis Pharma authorised in the EU?

The European Medicines Agency decided that Lonapegsomatropin Ascendis Pharma's benefits are greater than its risks and it can be authorised for use in the EU. The medicine was shown to be effective both in patients previously treated with growth hormone and newly diagnosed patients who had not yet been treated, and the weekly injections were preferred by most patients. The short-term safety appears to be in line with other growth hormone products; although any longer-term risk from the carrier part of the active substance seems unlikely, this will be closely monitored after marketing.

## What measures are being taken to ensure the safe and effective use of Lonapegsomatropin Ascendis Pharma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lonapegsomatropin Ascendis Pharma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lonapegsomatropin Ascendis Pharma are continuously monitored. Suspected side effects reported with Lonapegsomatropin Ascendis Pharma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lonapegsomatropin Ascendis Pharma

Lonapegsomatropin Ascendis Pharma received a marketing authorisation valid throughout the EU on 11 January 2022.

Lonapegsomatropin Ascendis Pharma  : EPAR - Medicine Overview

Reference Number: EMA/740430/2021

English (EN) (93.55 KB - PDF)

**First published:** 04/02/2022

[View](/en/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-262)

български (BG) (120.68 KB - PDF)

**First published:**

04/02/2022

[View](/bg/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_bg.pdf)

español (ES) (94.88 KB - PDF)

**First published:**

04/02/2022

[View](/es/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_es.pdf)

čeština (CS) (117.03 KB - PDF)

**First published:**

04/02/2022

[View](/cs/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_cs.pdf)

dansk (DA) (94.23 KB - PDF)

**First published:**

04/02/2022

[View](/da/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_da.pdf)

Deutsch (DE) (98.01 KB - PDF)

**First published:**

04/02/2022

[View](/de/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.28 KB - PDF)

**First published:**

04/02/2022

[View](/et/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (119.42 KB - PDF)

**First published:**

04/02/2022

[View](/el/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_el.pdf)

français (FR) (95.6 KB - PDF)

**First published:**

04/02/2022

[View](/fr/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (114.41 KB - PDF)

**First published:**

04/02/2022

[View](/hr/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_hr.pdf)

italiano (IT) (93.04 KB - PDF)

**First published:**

04/02/2022

[View](/it/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (134.16 KB - PDF)

**First published:**

04/02/2022

[View](/lv/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (116.49 KB - PDF)

**First published:**

04/02/2022

[View](/lt/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_lt.pdf)

magyar (HU) (115.93 KB - PDF)

**First published:**

04/02/2022

[View](/hu/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_hu.pdf)

Malti (MT) (118.81 KB - PDF)

**First published:**

04/02/2022

[View](/mt/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (94.38 KB - PDF)

**First published:**

04/02/2022

[View](/nl/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_nl.pdf)

polski (PL) (119.1 KB - PDF)

**First published:**

04/02/2022

[View](/pl/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_pl.pdf)

português (PT) (95.24 KB - PDF)

**First published:**

04/02/2022

[View](/pt/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_pt.pdf)

română (RO) (141.88 KB - PDF)

**First published:**

04/02/2022

[View](/ro/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (115.25 KB - PDF)

**First published:**

04/02/2022

[View](/sk/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (113.69 KB - PDF)

**First published:**

04/02/2022

[View](/sl/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_sl.pdf)

Suomi (FI) (91.1 KB - PDF)

**First published:**

04/02/2022

[View](/fi/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_fi.pdf)

svenska (SV) (92.98 KB - PDF)

**First published:**

04/02/2022

[View](/sv/documents/overview/lonapegsomatropin-ascendis-pharma-epar-medicine-overview_sv.pdf)

Lonapegsomatropin Ascendis Pharma : EPAR - Risk management plan summary

English (EN) (1.24 MB - PDF)

**First published:** 04/02/2022

[View](/en/documents/rmp-summary/lonapegsomatropin-ascendis-pharma-epar-risk-management-plan-summary_en.pdf)

## Product information

Skytrofa : EPAR - Product Information

English (EN) (442.72 KB - PDF)

**First published:** 04/02/2022

**Last updated:** 19/06/2025

[View](/en/documents/product-information/skytrofa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-347)

български (BG) (632.95 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/bg/documents/product-information/skytrofa-epar-product-information_bg.pdf)

español (ES) (445.75 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/es/documents/product-information/skytrofa-epar-product-information_es.pdf)

čeština (CS) (594.78 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/cs/documents/product-information/skytrofa-epar-product-information_cs.pdf)

dansk (DA) (450.38 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/da/documents/product-information/skytrofa-epar-product-information_da.pdf)

Deutsch (DE) (487.51 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/de/documents/product-information/skytrofa-epar-product-information_de.pdf)

eesti keel (ET) (584.61 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/et/documents/product-information/skytrofa-epar-product-information_et.pdf)

ελληνικά (EL) (662.68 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/el/documents/product-information/skytrofa-epar-product-information_el.pdf)

français (FR) (549.15 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/fr/documents/product-information/skytrofa-epar-product-information_fr.pdf)

hrvatski (HR) (561.21 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/hr/documents/product-information/skytrofa-epar-product-information_hr.pdf)

íslenska (IS) (464.48 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/is/documents/product-information/skytrofa-epar-product-information_is.pdf)

italiano (IT) (505.83 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/it/documents/product-information/skytrofa-epar-product-information_it.pdf)

latviešu valoda (LV) (590.05 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/lv/documents/product-information/skytrofa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (598.12 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/lt/documents/product-information/skytrofa-epar-product-information_lt.pdf)

magyar (HU) (611.29 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/hu/documents/product-information/skytrofa-epar-product-information_hu.pdf)

Malti (MT) (640.59 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/mt/documents/product-information/skytrofa-epar-product-information_mt.pdf)

Nederlands (NL) (483 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/nl/documents/product-information/skytrofa-epar-product-information_nl.pdf)

norsk (NO) (462.91 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/no/documents/product-information/skytrofa-epar-product-information_no.pdf)

polski (PL) (612.82 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/pl/documents/product-information/skytrofa-epar-product-information_pl.pdf)

português (PT) (481.25 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/pt/documents/product-information/skytrofa-epar-product-information_pt.pdf)

română (RO) (634.72 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/ro/documents/product-information/skytrofa-epar-product-information_ro.pdf)

slovenčina (SK) (585.61 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/sk/documents/product-information/skytrofa-epar-product-information_sk.pdf)

slovenščina (SL) (601.97 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/sl/documents/product-information/skytrofa-epar-product-information_sl.pdf)

Suomi (FI) (480.33 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/fi/documents/product-information/skytrofa-epar-product-information_fi.pdf)

svenska (SV) (458.87 KB - PDF)

**First published:**

04/02/2022

**Last updated:**

19/06/2025

[View](/sv/documents/product-information/skytrofa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0036 22/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) : EPAR - All authorised presentations

English (EN) (1.66 MB - PDF)

**First published:** 04/02/2022

**Last updated:** 25/08/2022

[View](/en/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-514)

български (BG) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/bg/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/es/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/cs/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/da/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/de/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/et/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (1.73 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/el/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (1.69 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/fr/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/hr/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/is/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/it/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/lv/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/lt/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/hu/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/mt/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/nl/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/no/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/pl/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/pt/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/ro/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/sk/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (1.74 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/sl/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/fi/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (1.66 MB - PDF)

**First published:**

04/02/2022

**Last updated:**

25/08/2022

[View](/sv/documents/all-authorised-presentations/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Active substance Lonapegsomatropin International non-proprietary name (INN) or common name lonapegsomatropin Therapeutic area (MeSH) Growth and Development Anatomical therapeutic chemical (ATC) code H01AC09

### Pharmacotherapeutic group

Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])

## Authorisation details

EMA product number EMEA/H/C/005367

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Ascendis Pharma Endocrinology Division A/S

Tuborg Boulevard 12

Opinion adopted 11/11/2021 Marketing authorisation issued 11/01/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (184.08 KB - PDF)

**First published:** 25/08/2022

**Last updated:** 19/06/2025

[View](/en/documents/procedural-steps-after/skytrofa-previously-lonapegsomatropin-ascendis-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Skytrofa-H-C-PSUSA-00010969-202402 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/53391/2025

English (EN) (145.62 KB - PDF)

**First published:** 12/02/2025

[View](/en/documents/scientific-conclusion/skytrofa-h-c-psusa-00010969-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Skytrofa-H-C-PSUSA-00010969-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/50448/2023

English (EN) (113.13 KB - PDF)

**First published:** 31/01/2023

[View](/en/documents/scientific-conclusion/skytrofa-h-c-psusa-00010969-202202-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Lonapegsomatropin Ascendis Pharma : EPAR - Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000059751

English (EN) (496.44 KB - PDF)

**First published:** 17/02/2022

**Last updated:** 16/03/2022

[View](/en/documents/orphan-maintenance-report/lonapegsomatropin-ascendis-pharma-epar-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Lonapegsomatropin Ascendis Pharma : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/706519/2021

English (EN) (2.41 MB - PDF)

**First published:** 04/02/2022

**Last updated:** 16/03/2022

[View](/en/documents/assessment-report/lonapegsomatropin-ascendis-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Lonapegsomatropin Ascendis Pharma

Adopted

Reference Number: EMA/CHMP/615593/2021

English (EN) (141.27 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-lonapegsomatropin-ascendis-pharma_en.pdf)

#### News on Skytrofa (previously Lonapegsomatropin Ascendis Pharma)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

#### More information on Skytrofa (previously Lonapegsomatropin Ascendis Pharma)

- [EU/3/19/2213 - orphan designation for treatment of growth hormone deficiency](/en/medicines/human/orphan-designations/eu-3-19-2213)
- [A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin (SkyPASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/50672)

**This page was last updated on** 12/02/2025

## Share this page

[Back to top](#main-content)